Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Show more

Location: 700 Quince Orchard Road, Gaithersburg, MD, 20878, United States | Website: https://www.novavax.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.105B

52 Wk Range

$5.01 - $11.55

Previous Close

$6.80

Open

$6.61

Volume

4,094,572

Day Range

$6.52 - $6.72

Enterprise Value

620.9M

Cash

762.9M

Avg Qtr Burn

-94.58M

Insider Ownership

8.75%

Institutional Own.

60.74%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

Approved

Update

Approved

Update

Approved

Update

Phase 3

Update

Phase 3

Update

Phase 2

Update

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued